📇 Rhumatologue · PARIS · (75) · Libéral
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Auteur de référence en rhumatologie
24 articles scientifiques publiés — un praticien à la pointe de la recherche
Référence presse grand public
Cité 6 fois dans les médias — pédagogie reconnue
Délais de RDV courts dans la région
336.2 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
CABINET DU DR PHILIPPE JEANNIN
2 RUE DE CIVRY, 75016 PARIS
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).
📰 Top Santé · 15/11/2024
<a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxQWHhRdVEtOWdmX1lHMnFRRHBMRDhoNmFUMTVjNHVnOHBMcHA2VE5OZXNaT3hqSXVlQnNfSEtLdTltbWlTdDVvYVhybUdTNnRYYnlmdW9GWHBaSEh0NnE2UXdmUW5DQUI5VXZablFMSzZHM3lzTlZid1NCOExHR3N3SXBoZlBwdlhqNUlIelAyTHpyLWprY1VzQTNGNFAweWN5NE5GaTZVc2lpNEZOUEJqSnFvWTNOa205M1
📰 RoseUp Association · 12/11/2019
<a href="https://news.google.com/rss/articles/CBMicEFVX3lxTE9GaGw3U25zT3Q5SEp4Z2VxaDZmaGwtTmdhejU0VWk2OVlIX2J3a2FXdlktRGRCYVdhMVZxMTdHdXFNTFltNTBPMVFNY2tXZzd5SnlGYUFNN2F3OHhwUXgxODNCQTFjZW5OS052UFBybXo?oc=5" target="_blank">Douleurs neuropathiques : vers une meilleure prise en charge</a> <font color
📰 RoseUp Association · 02/11/2018
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxNNE1EdUIzNXFfZ2RTT0xSQl81cE53bXptdXBwRm9sck9WOHJJRHNmUjN5SE5EaUVNQXhGNVdLb0ZwOFMwNFhmMy1Ddnd4Z05IczFRcXBiTERic0FNamlQN1NRNEtieFdJWUtxc2hDQTZNelpNT1FveFZzdklVZHpIMXotcGhVakdTX3ZtdnFqeWhXZ1FOSTlMTzlR?oc=5" target="_blank">Bérangère Arnal : l
📰 RoseUp Association · 09/05/2018
<a href="https://news.google.com/rss/articles/CBMiaEFVX3lxTE9VYXNWcE41bVRUdmx4aWhWSjdsS3pLSjA2Z3BxMk4tbW8yM0ljY0lZLWlfX0xpdkp3RXRlYnRneThVSFlySU5sd0VRa3pxZzE3VE1TREE1X1ZtMmlEU1VfcUVIQmwwbWdE?oc=5" target="_blank">La HOLI, une bulle d’oxygène dans les Landes</a> <font color="#6f6f6f">RoseUp Associati
📰 Le Populaire du Centre · 22/11/2017
<a href="https://news.google.com/rss/articles/CBMi4AFBVV95cUxQbi1PNGZ2a3l1ZzRoWUNpUmRyaHlORV9WWnZMY2lUak5Sck9lRUhhRVZ6dEVxbEkyQmlpWksyc21MUFlETlhzWXl2RGZVME1IR19HMEI0SVM1M1plclc4RkN3UzVfVS1pTUhoZjFSbnB5dXNvU0c4aHVFZUxqOURyMXNLdTJ6aUtKRU5TSWR2YllKOWVKWjZyMWtUZGthNEpzZHJraW1KeFVyVnZTcjZQQXNxZEFtc0NlVX
📰 Le Figaro Santé · 29/08/2017
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxPa21ldm5qRElnWTQzV1M3MzJSSHdrWExwQnRDcW1EOVBQd1ZNbnJyeTB2VzAwaGFsTy1YNlY3UGZZN2NPdVZRcG1tUzZHWHlRT05selF1TnFLb0RNQmxHOUw2ZzhDM244a0F6RkxIMEdrWFJJWU15S2V5YzcwRlFveUJUaXZCYlV0UFpFN2dwR2NzZw?oc=5" target="_blank">Comment l’acupuncture est uti
Journal of immunology (Baltimore, Md. : 1950) · 2009
Abstract IL-27 is formed by the association of a cytokine subunit, p28, with the soluble cytokine receptor EBV-induced gene 3 (EBI3). The IL-27R comprises gp130 and WSX-1. The marked difference between EBI3−/− and WSX-1−/− mice suggests that p28 has functions independent of EBI3. We have identified an alternative secreted complex formed by p28 and the soluble cytokine receptor cytokine-like factor 1 (CLF). Like IL-27, p28/CLF is produced by dendritic cells and is biologically active on human NK cells, increasing IL-12- and IL-2-induced IFN-γ production and activation marker expression. Experiments with Ba/F3 transfectants indicate that p28/CLF activates cells expressing IL-6Rα in addition to the IL-27R subunits. When tested on CD4 and CD8 T cells, p28/CLF induces IL-6Rα-dependent STAT1 and STAT3 phosphorylation. Furthermore, p28/CLF inhibits CD4 T cell proliferation and induces IL-17 and IL-10 secretion. These results indicate that p28/CLF may participate in the regulation of NK and T cell functions by dendritic cells. The p28/CLF complex engages IL-6R and may therefore be useful for therapeutic applications targeting cells expressing this receptor. Blocking IL-6R using humanized mAbs such as tocilizumab has been shown to be beneficial in pathologies like rheumatoid arthritis and juvenile idiopathic arthritis. The identification of a new IL-6R ligand is therefore important for a complete understanding of the mechanism of action of this emerging class of immunosuppressors.
Journal of immunology (Baltimore, Md. : 1950) · 2017
Abstract In physiological conditions, self-DNA released by dying cells is not detected by intracellular DNA sensors. In chronic inflammatory disorders, unabated inflammation has been associated with a break in innate immune tolerance to self-DNA. However, extracellular DNA has to complex with DNA-binding molecules to gain access to intracellular DNA sensors. IL-26 is a member of the IL-10 cytokine family, overexpressed in numerous chronic inflammatory diseases, in which biological activity remains unclear. We demonstrate in this study that IL-26 binds to genomic DNA, mitochondrial DNA, and neutrophil extracellular traps, and shuttles them in the cytosol of human myeloid cells. As a consequence, IL-26 allows extracellular DNA to trigger proinflammatory cytokine secretion by monocytes, in a STING- and inflammasome-dependent manner. Supporting these biological properties, IL-10–based modeling predicts two DNA-binding domains, two amphipathic helices, and an in-plane membrane anchor in IL-26, which are structural features of cationic amphipathic cell-penetrating peptides. In line with these properties, patients with active autoantibody-associated vasculitis, a chronic relapsing autoimmune inflammatory disease associated with extensive cell death, exhibit high levels of both circulating IL-26 and IL-26–DNA complexes. Moreover, in patients with crescentic glomerulonephritis, IL-26 is expressed by renal arterial smooth muscle cells and deposits in necrotizing lesions. Accordingly, human primary smooth cells secrete IL-26 in response to proinflammatory cytokines. In conclusion, IL-26 is a unique cationic protein more similar to a soluble pattern recognition receptor than to conventional cytokines. IL-26 expressed in inflammatory lesions confers proinflammatory properties to DNA released by dying cells, setting up a positive amplification loop between extensive cell death and unabated inflammation.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
The Journal of infectious diseases · 2025 · Journal Article
Legros V, Belarbi E, Jeannin P, Geolier V, et al.
Frontiers in immunology · 2020 · Journal Article
Brilland B, Vinatier E, Subra JF, Jeannin P, et al.
Journal of immunology (Baltimore, Md. : 1950) · 2017 · Journal Article
Poli C, Augusto JF, Dauvé J, Adam C, et al.
Parasites & vectors · 2016 · Journal Article
Lebon W, Tielemans E, Rehbein S, Dumont P, et al.
Parasitology research · 2016 · Journal Article
Rehbein S, Fourie JJ, de Vos C, Anderson A, et al.
Gut · 2015 · Comparative Study
Miot C, Beaumont E, Duluc D, Le Guillou-Guillemette H, et al.
American journal of medical genetics. Part A · 2013 · Case Reports
Janssen A, Hosen MJ, Jeannin P, Coucke PJ, et al.
PLoS biology · 2012 · Journal Article
Corvaisier M, Delneste Y, Jeanvoine H, Preisser L, et al.
Journal of immunology (Baltimore, Md. : 1950) · 2009 · Journal Article
Crabé S, Guay-Giroux A, Tormo AJ, Duluc D, et al.
Clinical reviews in allergy & immunology · 2008 · Journal Article
Beauvillain C, Delneste Y, Renier G, Jeannin P, et al.
Annales de biologie clinique · 2008 · Comparative Study
Galati S, Beauvillain C, Renier G, Jeannin P, et al.
Annals of the rheumatic diseases · 2007 · Letter
Dubois-Galopin F, Beauvillain C, Dubois D, Pillet A, et al.
Journal of the American Veterinary Medical Association · 2002 · Clinical Trial
Medleau L, Hnilica KA, Lower K, Alva R, et al.
Veterinary dermatology · 1995 · Journal Article
Postal JR, Jeannin PC, Consalvi PJ
Cellular immunology · 1993 · Journal Article
Delneste Y, Lassalle P, Jeannin P, Mannessier L, et al.
Journal of the American Society of Nephrology : JASN · 2026 · Journal Article
Brilland B, Riou J, Quéméneur T, Vandenbussche C, et al.
Clinical kidney journal · 2023 · Journal Article
Brilland B, Boud'hors C, Wacrenier S, Blanchard S, et al.
Autoimmunity reviews · 2020 · Journal Article
Brilland B, Garnier AS, Chevailler A, Jeannin P, et al.
Frontiers in immunology · 2021 · Journal Article
Brilland B, Bach-Bunner M, Gomes CN, Larochette V, et al.
Rheumatology (Oxford, England) · 2009 · Letter
Augusto JF, Onno C, Blanchard S, Dubuquoi S, et al.
Clinical and experimental immunology · 2004 · Comparative Study
Hebbar M, Jeannin P, Magistrelli G, Hatron PY, et al.
Journal of clinical medicine · 2022 · Journal Article
Urbanski G, Gury A, Jeannin P, Chevailler A, et al.
Clinical and experimental immunology · 2004 · Comparative Study
Hebbar M, Jeannin P, Magistrelli G, Hatron PY, et al.
Parasitology research · 2017 · Journal Article
Rehbein S, Knaus M, Mallouk Y, Breiltgens T, et al.
PloS one · 2016 · Journal Article
Simon A, Subra JF, Guilpain P, Jeannin P, et al.